SOWAHB: A Potential Drug Target and Biomarker for Ankyrin Repeat Domain-Containing Proteins

Target Name: SOWAHB

NCBI ID: G345079

SOWAHB

SOWAHB: A Potential Drug Target and Biomarker for Ankyrin Repeat Domain-Containing Proteins

Introduction

Ankyrin repeat domain-containing proteins (ARDPPs) are a family of transmembrane proteins that play crucial roles in various cellular processes. These proteins have been implicated in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. One of the ARDPPs, SOWAHB ( S Ronghua domain), has recently emerged as a promising drug target and biomarker due to its unique structure and function. In this article, we will provide an overview of SOWAHB, its potential drug target properties, and its potential as a biomarker for various diseases.

Structure and Function

SOWAHB is a 25 kDa protein that consists of an N-terminal cytoplasmic domain, a transmembrane region, and a C-terminal T-cell receptor (TCR) domain. The SOWAHB protein has a unique structure that consists of a long N-terminal cytoplasmic domain, a transmembrane region, and a short C-terminal TCR domain. The N-terminal cytoplasmic domain is rich in amino acids that are involved in the formation of a hydrophobic core, which is believed to play a structural role in the protein's stability and localization in the membrane.

The SOWAHB transmembrane region is characterized by a single transmembrane alpha helix, which is thought to be responsible for the protein's stability and its ability to interact with various cellular signaling pathways. The SOWAHB TCR domain is a short, 11 amino acid long, conserved region that is located at the protein's C-terminus.

SOWAHB has been shown to play various roles in cellular signaling pathways, including T cell development, T cell activation, and T cell receptor (TCR) signaling. SOWAHB has been shown to be involved in the regulation of TCR-CDK interactions, which are critical for T cell activation and proliferation.

Potential Drug Target

SOWAHB's unique structure and function make it an attractive drug target. The N-terminal cytoplasmic domain, which is rich in amino acids, can be targeted by small molecules or antibodies that can alter its stability or localization in the membrane. Additionally, the SOWAHB TCR domain can be targeted by antibodies that recognize and interact with specific residues within the domain.

SOWAHB has been shown to interact with various small molecules, including inhibitors of the protein kinase kinase (PKP) pathway. PKP is a highly conserved protein that is involved in various cellular signaling pathways, including T cell activation and proliferation. SOWAHB has been shown to interact with the protein Pyvg, which is a negative regulator of the PKP pathway.

In addition to its interactions with PKP, SOWAHB has also been shown to interact with several other small molecules, including inhibitors of the protein tyrosine phosphatase (PTP) pathway. PTP is a conserved protein that is involved in various cellular signaling pathways, including cell signaling , DNA replication, and neurotransmission.

Potential Biomarkers

SOWAHB's unique structure and function make it an attractive biomarker for various diseases. The N-terminal cytoplasmic domain, which is rich in amino acids, can be used as a biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

SOWAHB has been shown to interact with various proteins that are involved in the development and progression of neurodegenerative disorders, including beta-amyloid neurodegeneration and Alzheimer's disease. Additionally, SOWAHB has been shown to interact

Protein Name: Sosondowah Ankyrin Repeat Domain Family Member B

The "SOWAHB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SOWAHB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets